市場調查報告書

藥物安全檢測市場:臨床實驗階段(前臨床,第一階段,第二階段,第三階段,第四階段臨床實驗),服務供應商的類型,地區別預測

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast 2019-2024

出版商 IndustryARC 商品編碼 422640
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Back to Top
藥物安全檢測市場:臨床實驗階段(前臨床,第一階段,第二階段,第三階段,第四階段臨床實驗),服務供應商的類型,地區別預測 Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast 2019-2024
出版日期: 2018年12月23日內容資訊: 英文
簡介

本報告提供全球藥物安全檢測市場相關調查,彙整市場趨勢與策略性分析,各臨床實驗階段,服務供應商的各類型,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 藥物安全檢測市場:概要

第2章 摘要整理

第3章 市場環境

  • 市場佔有率分析
  • 競爭分析
  • 產品基準
  • 終端用戶分析
  • 前五名公司的財務分析

第4章 市場力量

  • 促進要素
  • 阻礙要素
  • 機會
  • 課題
  • 波特五力分析

第5章 策略性分析

  • 價值鏈分析
  • 價格分析
  • 機會分析
  • 產品/市場生命週期分析
  • 供給者和經銷商

第6章 各臨床實驗階段

  • 前臨床
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段臨床實驗

第7章 服務供應商的各類型

  • 公司內部
  • 委託外包

第8章 各地區市場

  • 歐洲
  • 亞太地區
  • 北美
  • 其他

第9章 市場熵

  • 擴大
  • 技術發展
  • 合併·收購,合資企業
  • 供給 - 契約

第10章 企業簡介

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reactions. Globally, increasing incidence rates of ADR (adverse drug reaction) which also represent a substantial burden on healthcare systems, coupled with the introduction of stringent government policies in developing nations pertaining to drug safety regulations are some key factors expected to drive the pharmacovigilance market during the period of study.

Geographically, North America dominated the pharmacovigilance market driven by strict drug safety approval regulations imposed by the U.S. FDA and other regulatory authorities coupled with increasing pressure for maintaining electronic medical records (EMR). North America was followed by Europe and Asia-Pacific as second and third largest market for the pharmacovigilance market. Asia Pacific is projected to have the fastest growth, owing to availability of large pool of educated and cost-effective labor force, the presence of favorable business environment and the implementation of government initiatives aimed at improving healthcare access in developing nations such as India and China.

This report identifies the pharmacovigilance market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the pharmacovigilance market.

This report segments the pharmacovigilance market on the basis of clinical trial phase, type of service provider and regional market as follows:

Pharmacovigilance market research report is classified on the basis of clinical trial phase. Some of the major clinical trial phases covered in this report are as follows: Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial

Pharmacovigilance market research report is classified on the basis of type of service provider. Some of the major service provider types covered in this report are as follows: In House, Contract Outsourcing

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the pharmacovigilance market. Some of the major companies' profiles in detail are as follows:

Quintiles Transnational Corporation

Accenture Plc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

PAREXEL International Corporation

Table of Contents

1. Pharmacovigilance Market - Overview

2. Executive Summary

3. Pharmacovigilance Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Pharmacovigilance Market- Forces

  • 4.1. Drivers
    • 4.1.1. Strict drug regulations in developed nations
  • 4.2. Restraints
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Pharmacovigilance Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Pharmacovigilance Market, By Clinical Trial Phase

  • 6.1. Preclinical Studies
  • 6.2. Phase I/1
  • 6.3. Phase II/2
  • 6.4. Phase III/3
  • 6.5. Phase IV/4 Trial

7. Pharmacovigilance Market, By Type of Service Provider

  • 7.1. In House
  • 7.2. Contract Outsourcing

8. Pharmacovigilance Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Pharmacovigilance Market - Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 10.1. Quintiles Transnational Corporation
  • 10.2. Accenture Plc.
  • 10.3. Boehringer Ingelheim GmbH
  • 10.4. Bristol-Myers Squibb
  • 10.5. PAREXEL International Corporation
  • 10.6. Janssen Research & Development, LLC
  • 10.7. Pharmaceutical Product Development, Inc.
  • 10.8. United BioSource Corporation
  • 10.9. Synowlwedge LLC
  • 10.10. Cognizant Technology Solutions Corporation
  • 10.11. Covance Inc.
  • 10.12. ICON, Plc..

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top